Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial - An update

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Haggag, Rasha ^a   Farag, Kamel ^b   Abu Taleb, Fouad ^a   Shamaa, Sameh ^b   Zekri, Abdel Rahman ^c   Elbolkainy, Tarek ^d   Khaled, Hussein ^c  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

Bladder cancer; Cisplatin; Low dose gemcitabine; Prolonged infusion

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ANEMIA; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

MLCS; MLOWN;

EID: 84891865494     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0811-5     Document Type: Conference Paper

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed May 6, 2012.
2. American Cancer Society: Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013. Available online. Accessed March 13, 2013.
3. Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy NM. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Cancer Inst. 2007;19(2):158.
4. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity MVAC chemotherapy and G-CSF vs. classic MVAC in advanced urothelial tract tumors. Eur J Cancer. 2006;42:50-4. (Pubitemid 41814532)
5. Von der Masse H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicancer, phase III study. J Clin Oncol. 2000;18:3068-77.
6. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-8. (Pubitemid 46224062)
7. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995;22(11):19-25.
8. Heinemann V, Schukz L, Issels RD, et al. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 1995;22(Suppl 11):11-8.
9. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(Suppl 11):3-10.
10. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27(4):258-62.
11. Khaled H, Emara ME, Gaafar RM, Mansour O, Abdel Warith A, Zaghloul MS, El Malt O. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol Oncol. 2008;26(2):133-6. (Pubitemid 351288557)
12. Khaled H, Abu-Taleb F, Haggag R, and Zekri A (2011) Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial. J Clin Oncol 29: (suppl 7; abstr 266).
13. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-81. (Pubitemid 29470648)
14. López-Gómez M, Malmierca E, de Górgolas M, Casado E. Cancer in developing countries: The next most preventable pandemic. The global problem of cancer. Crit Rev Oncol Hematol. 2013 Apr 18. pii: S1040-8428(13)00071-1. doi: 10.1016/j.critrevonc.2013.03.011. [Epub ahead of print].
15. Heinrich J, Mielck A. Social inequality and environmentally-related diseases in Germany: review of empirical results. Soz-Präventivmed. 2000;45:106-18. (Pubitemid 30444970)
16. Khaled HM, Hamza MR, Mansoyr O, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur J Cancer. 2000;36(Suppl 2):34-7.
17. Moore MJ, Winquist EW, Murray N. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial if the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876-81. (Pubitemid 29415247)
18. Kaufman D, Raghavan D, Carducci M. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921-7. (Pubitemid 30261930)
19. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol. 2009;4(9):1148-55.